---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073312"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:27:34.238995+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Kyverna presents data update on KYV-101 CAR T therapy at EULAR symposium

## Summary
- CEO Peter Maag introduced symposium; external speakers presented long-term clinical experience with anti-CD19 CAR T in autoimmune diseases.
- KYV-101 data covered experience across multiple autoimmune diseases and sites, presented by James Chung, MD, PhD of Kyverna.
- Panel discussion featured academic and Kyverna experts on KYV-101's potential in rheumatologic autoimmune indications.
- No specific numerical efficacy or safety results were disclosed in the furnished presentation materials.

## SEC filing metadata
- accession: 0000950170-24-073312
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017024073312/0000950170-24-073312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017024073312/kytx-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073312
- JSON: https://secwatch.observer/filing/0000950170-24-073312.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.